Delivery Order SPE2DB20D3101-SPE2DB25FRVG4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $20,957.72 to AmerisourceBergen Drug Corp for the supply of MYRBETRIQ ER 50 mg tablets (90-count units). This competitive award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (90-count supply) on September 9, 2025, with a ceiling value of $3,650.59. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a non-competitive set-aside contract. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $7,794.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count unit). The contract utilizes firm fixed-price pricing with an ultimate completion date of July 29, 2025, and represents a non-competitive, non-set-aside award. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1...
- The Defense Logistics Agency awarded a delivery order valued at $1,923.12 to AmerisourceBergen Drug Corp for Myrbetriq ER 25 mg tablets (90-count supply) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $4,512.00 delivery order on July 21, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price contract with a completion date of July 22, 2025, and represents a non-set-aside competitive award. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $1,720.92 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (30-count supply) on September 9, 2025, with completion targeted for September 10, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing pharmaceutical supply agreements with DLA. The medication will be delivered to the company's corporate office location...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a Delivery Order valued at $9,586.26 by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 13, 2025, and represents a non-set-aside procurement. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of MYRBETRIQ ER 50 MG tablets. The $5,448.95 contract has a completion date of March 12, 2024 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,290.75 on September 10, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count). This is a firm fixed price, non-set-aside contract with a completion date of September 11, 2025, and performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $4,869.59 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used in the treatment of overactive bladder. The contract was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and represents a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRVG4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,866.33 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 25 MG tablets (90 count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This firm fixed price, non-set-aside contract represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency and military healthcare systems. The SPE2DX prime vendor contract functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical supplies to support military healthcare programs worldwide. This delivery order for MYRBETRIQ, a treatment for overactive bladder, exemplifies the company's role in fulfilling routine pharmaceutical supply needs for the federal government through competitively awarded agreements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.9k | 9/12/25 |